StemCell Therapy

Doctor from Korea is talking about breast enhancement using stem cell technology

Go here to read the rest:

Doctor discussing fat stem cell therapy - Video

Dr. David Genecov uses a patient's fat for facial reconstruction.

See the original post here:

WFAA Story -- Fat and Stem Cells Used for Reconstruction - Video

Dr Malans Natural Breast Augmentation technique employs the latest technologic advances in fat harvesting, adult stem cell transfers, and breast splinting technology to provide women the option of enlarging their breast using their own fat.

See more here:

Fat Transfer Breast Augmentation | Stem Cell | Dr. Todd Malan - Video

Stem cells from fat may help heal bone

June 30, 2010

Wounded soldiers may one day be treated with stem cells from their own fat using a method under development at UC Davis.

Kent Leach, assistant professor of biomedical engineering, has already used the treatment in three racehorses. Now, with a $100,000 grant from the U.S. Army, he will begin testing it in rats.

The method employs a gel-like material to encourage stem cells from fat to regenerate damaged bone.

The stem cells have been shown to stimulate the growth of small blood vessels in developing bone, encouraging healing. The gel keeps the stem cells at the injury site; as the bone heals, the gel breaks down.

"Straight injection of stem cells has a limited effect," Leach said. "If we can localize the cells at the treatment site, the treatments should be more effective."

With Larry Galuppo, professor of veterinary medicine at UC Davis, Leach has already tested the technique in racehorses undergoing treatment for bone cysts at the UC Davis Veterinary Medical Teaching Hospital. Galuppo and his colleagues are treating most of the horses by injecting them with stem cells alone, but in three horses to date, they have used Leach's gel method. Results from those equine patients are still being assessed. The technique has not yet been tested in humans.

Using stem cells from a patient's own fat has two main advantages, Leach said. The stem cells have a better chance of succeeding and not being rejected by the body; and the main alternative, extraction from bone marrow, can be painful, requires several days of recovery time, and is not feasible for severely injured or weakened patients.

"Stem cells from adipose tissue are an exciting alternative to stem cells from bone marrow or other tissues because we can isolate a large number, no matter what the patient’s condition is," Leach said.

Leach envisions that eventually, surgeons could extract fat from a patient, separate out the stem cells, mix them into the gel and inject the mixture directly into a fracture.

The team will test several compositions in rats to find one that yields the most rapid growth of new blood vessels and resulting bone formation, using noninvasive imaging technologies.

Leach's grant from the U.S. Army was awarded through the Office of Congressionally Directed Medical Research Programs.

source UC Davis ED

Arthritis Patient Successfully Treated With Fat Stem Cells Tells His Story

SAN DIEGO, CA--(Marketwire - June 28, 2010) - Medistem Inc. (PINKSHEETS: MEDS). Medistem collaborator Dr. Jorge Paz Rodriquez was invited to give a talk at Del Mar College in Texas by arthritis patient Dusty Durrill. The patient described a profound recovery after treatment with stem cells from his own fat tissue. Mr Durrill underwent a procedure in which a small amount of fat tissue was extracted by liposuction, stem cells where purified, and subsequently injected intravenously.

This procedure has been used successfully to treat thousands of animals suffering from arthritis in the United States (www.vet-stem.com). Use of patient's own stem cells is currently being performed in the United States (www.regenexx.com). Recently Dr. Paz published a paper describing scientific mechanisms of this treatment in collaboration with scientists from the University of California San Diego, University of Western Ontario, and Medistem Inc (Ichim et al. Autologous stromal vascular fraction cells: A tool for facilitating tolerance in rheumatic disease. Cell Immunol. 2010 Apr 8).

"I had treatment for my arthritis, I was not wheelchair bound but I was getting there... after stem cell treatment my arthritis symptoms disappeared," stated Mr. Durrill.

More than 200 people attended the lecture including the general public, patients and medical doctors. The lecture was focused on US and European clinical trials supporting the use of adult stem cells in conditions ranging from multiple sclerosis, to heart failure, to diabetes. A video of part of the lecture is available at http://www.kiiitv.com/younews/97165699.html.

Dr. Paz commented, "Mr. Durrill suffered from arthritis for more than ten years with severe pain in both knees and hips. He had difficulty standing and limited mobility. After stem cell therapy he started showing significant reduction in pain. Now about a month after therapy he is pain free and can move around easily."

Drs. Robert Harman, CEO of Vet-Stem and Thomas Ichim, CEO of Medistem, recently released a video discussing their publication on fat stem cell therapy for arthritis. The video is available at http://www.youtube.com/watch?v=3QQrwtp-KQQ.

About Medistem Inc.

Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company's lead product, the endometrial regenerative cell (ERC), is a "universal donor" stem cell being developed for critical limb ischemia. A publication describing the support for use of ERC for this condition may be found at http://www.translational-medicine.com/content/pdf/1479-5876-6-45.pdf

Cautionary Statement

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.